A study on pharmacokinetics, pharmacodynamics and safety of lixisenatide in children and adolescents with type 2 diabetes.

Margarita Barrientos-PérezDaniel S HsiaLance SloanHaylene NellOunisha MungurLionel HovsepianWolfgang SchmiderRobert SprangerNa YangElisabeth Niemoeller

Published in: Pediatric diabetes (2022)

Mean lixisenatide concentrations generally increased with increasing dose, irrespective of ADA status. Lixisenatide was associated with improved glycemic control and a trend in body weight reduction compared with placebo. The safety and tolerability profile of repeated lixisenatide doses of up to 20 μg per day in children and adolescents with T2D was reflective of the established safety profile of lixisenatide in adults.

Keyphrases

body weight
glycemic control
type diabetes
blood glucose
randomized controlled trial
open label
clinical trial
weight loss
adipose tissue
placebo controlled